Live trials for COVID-19

COVID-19 trials

We are carrying out a number of trials for patients who are being treated at, or admitted to NUH for COVID-19.

Our research is part of the national and international response to COVID-19. Our expert clinical research teams are helping to find the most effective drugs, vaccines and treatments. Our aim is to offer every patient with suspected or confirmed COVID-19 the opportunity to take part in this vital research.

Taking part

If you are admitted or referred to NUH with suspected or confirmed COVID-19, your clinical team and our research nurses (who specialise in supporting patients taking part in clinical trials) will talk to you about taking part in COVID-19 research here.

Research trials into new COVID-19 vaccines are open to people who are healthy (and do not have COVID-19).

Trials for recovery from COVID-19

Trials looking at aspects of Long Covid

  • C-MORE - Capturing the MultiORgan Effects of COVID-19 is assessing the prevalence and extent of persistent multi-organ damage in survivors of COVID-19. Although COVID-19 primarily affects the lungs, some people can develop damage to other vital organs including the heart, brain, liver and kidney.

  • DYNAMO - DYNamic Assessment of Multi Organ level dysfunction in patients recovering from COVID-19. Volunteers will be followed-up 3-4 months after discharge from hospital.

  • NoRCoRP - the Nottingham Recovery from COVID-19 Research Platform (NoRCoRP) brings together a number of research projects looking at the impact of COVID-19 and the needs of patients recovering after the infection.
  • PHOSP COVID - involves 20 universities and their partner NHS trusts, as well as charity partners AUK-BLF. It aims to recruit 10,000 people, to understand the longer term effects of COVID-19 for patients after they leave hospital.

Vaccine trials

Vaccine trials

  • AmCOV study - is investigating why some people suffer “flu-like” symptoms after receiving a COVID-19 vaccine is about to start in Nottingham. Researchers at the NIHR Nottingham Biomedical Research Centre, the University of Nottingham and NUH will be using MRI scans to look for tiny changes in the brain which might explain the symptoms some people report. The study will use MRI, blood tests and questionnaires to help identify any changes in the brain and any physical symptoms before and after volunteers have had their COVID-19 vaccine as part of the national vaccine rollout programme. To find out more about the study you can email: Andrea Junor (Andrea.Junor@nottingham.ac.uk), who is one of the research team members, or Professor Dorothee Auer (Dorothee.Auer@nottingham.ac.uk) who is the doctor leading the study.

  • The Valneva “Cov-Compare” trial - Valneva’s Phase 3 clinical trial is testing a new vaccine (known as VLA2001) against COVID-19 and its ability to induce antibodies as a protection against the virus.

    The trial has now recruited 4,000 people aged 18 years and over in the UK to help evaluate the VLA2001 vaccine compared to a licensed COVID-19 vaccine. NUH was one of the locations running the trial and through our NIHR Nottingham Clinicla. Research Facility will be continuing to follow-up people who took part over the next year.

  • NHS COVID-19 Vaccine Registry - you can sign up to take part in future trials now as part of the national volunteer programme to find an effective vaccine.

Trials for COVID-19 tests

Developing new tests for COVID-19

  • COVID-19 SEROlogical antibody (Ab) testing - examining the effectiveness of enzyme-linked Immunosorbent assays (ELISA) for screening for IgG, A and M responses to multiple proteins of SARS-CoV-2 to support understanding of the scope of protective immunity generated in the population. The study will link the antibody response to clinical outcome of the patients to give a better understanding of the role of antibodies in providing protection.
  • FALCON - the Facilitating AcceLerated Clinical validation Of novel diagnostics for COVID-19 is a national trial to rapidly assess new diagnostic tests for COVID-19. Nationally the study will assess  approximately 10 new tests. Many of those tests are likely to be point of care tests, which can be done at the patient's bedside and which often return results in as little as five minutes

Treatment trials for COVID-19

Drug and treatment trials

  • ACCORD-2 - this is a national trial to fast-track the development of new drugs for treating COVID-19. It is a partnership between the NHS, the pharmaceutical industry and specialist research centres including the NIHR Nottingham Clinical Research Facility based at NUH.
  • ADAPT-Sepsis - this study builds on existing research into effective antiobiotic treatment for Sepsis, a life-threatening infection. Now the study is including seriously ill COVID-19 patients. This is particularly important for severe infections caused by coronavirus because there is no evidence that antibiotics are effective at treating viral infections.
  • RECOVERY - there are no specific treatments for COVID-19. This trial is investigating different drugs, currently used for other conditions, to see if they have benefits for patients with COVID-19. The Randomised Evaluation of COVid-19 thERapY (RECOVERY) trial will provide doctors and health services with information they need to determine which treatments should be used. Initially for adults, we have now extended this trial at NUH to include newborns, children and young people under the age of 18 years.
  • RECOVERY-RS - this trial is investigating the most effective way to administer oxygen to COVID-19 patients. Methods including CPAP and High Flow Nasal Oxygen (HFNO) are being used, comparing with more commonly used masks and nasal tubes.
  • REMAP-CAP  – this study is identifying the most clinically effective interventions for adult patients admitted to an intensive care unit with community-acquired pneumonia and COVID-19.

Trials expanding our knowledge of COVID-19

Trials making new discoveries about COVID-19

  • COVID-19-BMT- is a study investigating severe COVID-19 infection in allogeneic stem cell recipients. It involves both adults and children of any age who have received allogeneic stem cell transplantation and who have tested positive for COVID-19. 
  • EXCEED - led by the NIHR Leicester Biomedical Research Centre and the University of Leicester, this study is calling for volunteers to help understand why some people develop more severe COVID-19 than others – particularly those from black and minority ethnic communities.
  • GenOMICC – looking into the genetic susceptibility of patients to COVID-19 in critical care. This trial is aiming to find genetic markers which may help researchers and clinicians to identify patients who are at greater risk.
  • ISARIC  - NUH is already part of the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) which is working to investigate severe acute respiratory illnesses (SARI). Data from patients at NUH suspected of having, or who are confirmed with, COVID-19 is now being included in this research.
  • PANTHER - PANdemic Tracking of Healthcare woRkers; this study aims to deepen our understanding of susceptibility to, immunity from and transmission of Covid-19.
  • SAFE SURGERY - this study will provide initial scientific data to help determine risk to the theatre team of COVID-19 transmission via the peritoneal cavity in patients undergoing abdominal or pelvic surgery
  • VirusWatch - this study aims to identify how the virus spreads, and, how to stop it. Thousands of households already taking part; participants receive antibody tests to see if they have had COVID-19 and might now have resistance against the virus

COVID-19 trials for women and children

Trials involving women and children from 0-17 years

  • Neonatal complications of COVID-19 - this study is collecting information about newborn babies who have Coronavirus or who are born to mothers who have Coronavirus.
  • PAN-COVID - this study is looking at the impacts of COVID-19 on pregnant women and their babies. 
  • UKOSS - the UK Obstentrics Surveillance System (UKOSS) is collecting data from pregnant women who have a COVID-19 diagnosis to help understand more about how the virus may affect women and infants.

End of life care COVID-19 trials

These trials are looking at the impact on people at the end of life

  • COV-Pall - a rapid evaluation of the COVID-19 pandemic response in palliative and end of life care.

  • DIScOVER - comparing disability in activities of daily living for adults with advanced lung cancer or respiratory disease during the COVID-19 pandemic.

Finding new ways of working

Deatils of trials will appear here when they are live.

Completed trials

Thank you

These are the COVID-19 studies that have now been completed at NUH. 

Thank you to everyone who supported them and volunteered to take part.

  • COG-UK HOCI - this study is investigating how integrating rapid, real-time COVID-19 genomic sequencing can impact decision-making by infection control teams to prevent the spread of the SARS-CoV-2 virus in NHS hospitals. 
  • Com-Cov study - the purpose of this trial is to see how well people’s immune systems respond when their first dose is one type of vaccine, and their second is another. It will also see how good the response is when the second dose is separated from the first dose by different periods of time.
  • Communications and COVID-19 - this study is led by the Royal Free London NHS Foundation Trust and is open to healthcare workers to feedback their experiences. 
  • COVID-NURSE - is evaluating the impact on patient experience of a combination of nursing innovations. NUH is part of a consortium of universities and NHS trusts, working together to build the evidence that will help nursing teams nationally and internationally to adopt best practice for care during a pandemic.
  • Medical Detection Dogs - People with COVID-19 do not always have symptoms (asymptomatic). This study, led by the London School of Hygiene and Tropical Medicine, Durham University and the charity Medical Detection Dogs, is investigating whether dogs may be able to identify asymptomatic patients, as well as those who have mild symptoms (symptoms not requiring treatment, hospital stay or limiting normal activities).

  • Oxford Vaccine Trial - our experts in experimental medicine, based in our NIHR Nottingham Clinical Research Facility, are supporting the first national trial of a vaccine for COVID-19. Taking place at Cripps Health Centre on the University of Nottingham campus, this trial involves frontline health and social care staff aged over 18 years. Over 520 patients took part in this trial in Nottingham and will continue to be followed-up by the research team.

  • PACE - a study investigating the effects of COVID-19 for patients with acute myeloid leukemia (AML).
  • PRIEST – this study is investigating the most effective ways of triaging people with suspected respiratory infections in emergency care during a pandemic.
  • PREPARE-IBD - a study looking at the impacts of COVID-19 for people living with Inflammatory Bowel Disease to improve the treatment and care for patients in the future
  • PROTECT-ASUS - this study is looking at the treatment and care for patients with acute severe ulcerative colitis during the COVID-19 pandemic
  • Psychological impact of COVID-19 - this international study is aiming to better understand how Coronavirus and the restrictions necessary to prevent its spread are impacting on our day to day lifestyle. This study is using an online questionnaire and is open to anyone over the age of 16 years.
  • SIREN - this study aims to understand whether prior infection with SARS-CoV2 (the virus that causes COVID-19) protects against future infection with the same virus. Currently this trial is open to staff working at NUH.
  • SNG001 - this trial is investigating the use of a formulation of the drug, interferon beta, in adults with COVID-19. In this trial, patients will either receive the drug or a placebo (which does not contain any active drug). The drug will be given to patients using an inhaler.
  • What's the Story - this study involves donation of a blood sample from people aged from birth to-24 years of age to look at their antibody levels against important infectious diseases. The study is looking at Group C meningococcus (MenC) and diphtheria and now COVID-19.